Tasisulam(LY573636)|cas 519055-62-0|DC Chemicals|Price|Buy

Cas No.:	519055-62-0
Chemical Name:	Tasisulam
Synonyms:	Tasisulam;N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide;LY573636;N-(5-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide;N-(5-Bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide;UNII-1YC4W9MSLJ;1YC4W9MSLJ;519055-62-0;DTXSID20199869;FT-0763021;AS-38576;HY-14804;AC-32975;P7M;Tasisulam(LY573636);Tasisulam [INN];J-522818;EX-A1367;Q27253184;SW219181-1;CCG-268827;HMS3653O12;BCP05154;s7326;NCGC00386305-05;LY 573636 (sodium);Benzamide, N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichloro-;BCP9000890;NS00069285;519055-63-1;SB19401;CHEMBL2110587;Z442229142;Tasisulam (sodium);AKOS027250790;N-((5-BROMOTHIOPHEN-2-YL)SULFONYL)-2,4-DICHLOROBENZAMIDE;N-[(5-bromothiophen-2-yl)sulfonyl]-2,4-dichlorobenzamide;TASISULAM [WHO-DD];SCHEMBL1581371;Tasisulam (LY573636);LY-573636;DB11941;CS-0003569;LY 573636;MFCD11973637;EN300-6492968;Tasisulam(LY573636)?;CHEBI:231621;tasisulamum;DB-071449;LY573636 sodium;DTXCID30122360;BRD-K42495768-001-01-7;n-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
SMILES:	O=C(NS(=O)(C1=CC=C(Br)S1)=O)C2=CC=C(Cl)C=C2Cl
Formula:	C₁₁H₆NO₃S₂Cl₂Br
M.Wt:	415.11024
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Tasisulam is a small molecule antitumor agent that inhibits mitotic progression and induces vascular normalization. Tasisulam induces apoptosis via the intrinsic pathway[1].

In Vitro:

Tasisulam (200 μM-200 nM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC50s is 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively[1]. Tasisulam (25, 50 μM; 72 hours) induces a concentration-dependent increase in 4N DNA and G2-M accumulation[1]. Tasisulam (200 μM-200 nM; 48 hours) induces apoptosis in a broad range of in vitro cancer cell models[1]. Cell Proliferation Assay[1] Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 μM-200 nM Incubation Time: 48 hours Result: Induced an antiproliferative response across a wide range of tumor histologies with EC50s are 10 μM and 25 μM, respectively. Cell Cycle Analysis[1] Cell Line: Calu-6 and A-375 cell lines Concentration: 25, 50 μM Incubation Time: 72 hours Result: Induced a concentration-dependent increase in 4N DNA and G2-M accumulation. Apoptosis Analysis[1] Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 μM-200 nM Incubation Time: 48 hours Result: Induced apoptosis in a broad range of in vitro cancer cell models.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC60864	D927 (DS11252927)	D927 is a molecular glue and promotes glucose uptake in the absence of insulin. D927 also increases the affinity of RAS binding to PI3Kα by ~500-fold. In vivo, D927 mimicks the effects of insulin and rapidly lowers blood glucose concentrations.
DC60863	D223 (DS02312223)	D223 is a molecular glue and promotes glucose uptake in the absence of insulin. D223 also increases the affinity of RAS binding to PI3Kα by ~500-fold.
DC60858	LC-04-045	LC-04-045 is a leading NEK7 molecular glue degrader with DC50 of 7 nM and Dmax of 90 % in MOLT-4 cells. LC-04-045 displays high selectivity for NEK7 across the proteome.
DC60852	PVTX-405	PVTX-405 is a potent, effective, highly selective, and orally efficacious IKZF2 molecular glue degrader with DC50 of 0.7 nM. PVTX-405 in combination with anti-PD1 or anti-LAG3 significantly increases animal survival compared to anti-PD1 or anti-LAG3 alone.
DC60837	MGD-28	MGD-28 is a potent molecular glue degrader that demonstrates significant in vitro efficacy against various hematological cancer cell lines. It induces degradation of Ikaros family zinc finger proteins 1, 2, and 3 (IKZF1/2/3) and casein kinase 1 alpha (CK1α) with nanomolar potency via a Cullin-cereblon (CRBN) dependent pathway. Compared to lenalidomide and pomalidomide, MGD-28 achieves deeper, faster, and more potent degradation of these neosubstrates. Additionally, MGD-28 exhibits broad antiproliferative activity in multiple solid malignancies and shows preferential cytotoxicity toward multiple myeloma patient-derived cells at various disease stages.
DC67413	MRT-23227
DC67412	MRT-3486	MRT-3486 (Compound 5) is a cereblon-based NEK7 molecular glue degrader. MRT-3486 can be used for autoinflammatory diseases research.
DC67411	MRT-7612
DC67410	MRT-10350
DC67407	IKZF1-degrader-1	IKZF1-degrader-1 (Compound 9-B) is a highly potent molecular glue that achieves sub-nanomolar degradation of IKZF1 (DC50 = 0.134 nM), demonstrating significant therapeutic potential for targeting IKZF1-dependent malignancies.